PortalPublikationenAprepitant as salvage therapy in patients with chemotherapy-...

Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone

Standard

Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. / Oechsle, Karin; Müller, Martin R; Hartmann, Jörg T; Kanz, Lothar; Bokemeyer, Carsten.

in: ONKOLOGIE, Jahrgang 29, Nr. 12, 12.2006, S. 557-61.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Oechsle, K, Müller, MR, Hartmann, JT, Kanz, L & Bokemeyer, C 2006, 'Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone', ONKOLOGIE, Jg. 29, Nr. 12, S. 557-61. https://doi.org/10.1159/000096689

APA

Oechsle, K., Müller, M. R., Hartmann, J. T., Kanz, L., & Bokemeyer, C. (2006). Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. ONKOLOGIE, 29(12), 557-61. https://doi.org/10.1159/000096689

Vancouver

Oechsle K, Müller MR, Hartmann JT, Kanz L, Bokemeyer C. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. ONKOLOGIE. 2006 Dez;29(12):557-61. https://doi.org/10.1159/000096689

Bibtex

@article{db6d9ebb4d4c45e2bf2ab399f1c16766,
title = "Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone",
abstract = "BACKGROUND: Despite prophylaxis with 5-HT(3) antagonists and dexamethasone, nausea/emesis are common chemotherapy- induced toxicities. The aim of this trial was to evaluate the efficacy of adding the NK1 antagonist aprepitant in patients refractory to standard prophylaxis.PATIENTS AND METHODS: Patients with significant nausea/vomiting despite prophylaxis with 5-HT(3) antagonists and dexamethasone were eligible. Aprepitant was added to the same antiemetic regimen used during previous cycles.RESULTS: 34 patients received 92 cycles of chemotherapy with aprepitant which was applied orally at 125 mg on day 1 and 80 mg on days 2 and 3. All patients were refractory to standard antiemetic prophylaxis during cisplatin-based (n = 12) or other chemotherapy (n = 22). With the addition of aprepitant, all patients reported subjective improvement. The number of patients with nausea for >4 days decreased from 24 (71%) to 4 (12%) (p < 0.001), and the number of those with emesis for >2 days decreased from 26 (77%) to 0 (0%) (p < 0.001). In 12 patients receiving aprepitant for >2 cycles (3-8) the efficacy was maintained. No toxicity possibly related to aprepitant was observed.CONCLUSION: Aprepitant demonstrated significant activity in patients with nausea/vomiting refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.",
keywords = "Administration, Topical, Adult, Aged, Antiemetics, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Morpholines, Nausea, Neoplasms, Salvage Therapy, Serotonin 5-HT3 Receptor Antagonists, Serotonin Antagonists, Treatment Outcome, Vomiting",
author = "Karin Oechsle and M{\"u}ller, {Martin R} and Hartmann, {J{\"o}rg T} and Lothar Kanz and Carsten Bokemeyer",
year = "2006",
month = dec,
doi = "10.1159/000096689",
language = "English",
volume = "29",
pages = "557--61",
journal = "ONKOLOGIE",
issn = "0378-584X",
publisher = "S. Karger AG",
number = "12",

}

RIS

TY - JOUR

T1 - Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone

AU - Oechsle, Karin

AU - Müller, Martin R

AU - Hartmann, Jörg T

AU - Kanz, Lothar

AU - Bokemeyer, Carsten

PY - 2006/12

Y1 - 2006/12

N2 - BACKGROUND: Despite prophylaxis with 5-HT(3) antagonists and dexamethasone, nausea/emesis are common chemotherapy- induced toxicities. The aim of this trial was to evaluate the efficacy of adding the NK1 antagonist aprepitant in patients refractory to standard prophylaxis.PATIENTS AND METHODS: Patients with significant nausea/vomiting despite prophylaxis with 5-HT(3) antagonists and dexamethasone were eligible. Aprepitant was added to the same antiemetic regimen used during previous cycles.RESULTS: 34 patients received 92 cycles of chemotherapy with aprepitant which was applied orally at 125 mg on day 1 and 80 mg on days 2 and 3. All patients were refractory to standard antiemetic prophylaxis during cisplatin-based (n = 12) or other chemotherapy (n = 22). With the addition of aprepitant, all patients reported subjective improvement. The number of patients with nausea for >4 days decreased from 24 (71%) to 4 (12%) (p < 0.001), and the number of those with emesis for >2 days decreased from 26 (77%) to 0 (0%) (p < 0.001). In 12 patients receiving aprepitant for >2 cycles (3-8) the efficacy was maintained. No toxicity possibly related to aprepitant was observed.CONCLUSION: Aprepitant demonstrated significant activity in patients with nausea/vomiting refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.

AB - BACKGROUND: Despite prophylaxis with 5-HT(3) antagonists and dexamethasone, nausea/emesis are common chemotherapy- induced toxicities. The aim of this trial was to evaluate the efficacy of adding the NK1 antagonist aprepitant in patients refractory to standard prophylaxis.PATIENTS AND METHODS: Patients with significant nausea/vomiting despite prophylaxis with 5-HT(3) antagonists and dexamethasone were eligible. Aprepitant was added to the same antiemetic regimen used during previous cycles.RESULTS: 34 patients received 92 cycles of chemotherapy with aprepitant which was applied orally at 125 mg on day 1 and 80 mg on days 2 and 3. All patients were refractory to standard antiemetic prophylaxis during cisplatin-based (n = 12) or other chemotherapy (n = 22). With the addition of aprepitant, all patients reported subjective improvement. The number of patients with nausea for >4 days decreased from 24 (71%) to 4 (12%) (p < 0.001), and the number of those with emesis for >2 days decreased from 26 (77%) to 0 (0%) (p < 0.001). In 12 patients receiving aprepitant for >2 cycles (3-8) the efficacy was maintained. No toxicity possibly related to aprepitant was observed.CONCLUSION: Aprepitant demonstrated significant activity in patients with nausea/vomiting refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.

KW - Administration, Topical

KW - Adult

KW - Aged

KW - Antiemetics

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Dexamethasone

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Morpholines

KW - Nausea

KW - Neoplasms

KW - Salvage Therapy

KW - Serotonin 5-HT3 Receptor Antagonists

KW - Serotonin Antagonists

KW - Treatment Outcome

KW - Vomiting

U2 - 10.1159/000096689

DO - 10.1159/000096689

M3 - SCORING: Journal article

C2 - 17202825

VL - 29

SP - 557

EP - 561

JO - ONKOLOGIE

JF - ONKOLOGIE

SN - 0378-584X

IS - 12

ER -